DelveInsight’s “Palmoplantar Pustulosis (PPP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Palmoplantar Pustulosis market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Palmoplantar Pustulosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Palmoplantar Pustulosis: An Overview
Palmoplantar pustulosis (PPP) is an uncommon, chronic pustular condition affecting the palms and soles. Blisters and fluid-filled bumps, known as pustules, appear on the palms of the hands and the soles of the feet. It is a rare autoimmune condition and is more likely to affect people who currently or used to smoke. It is related to a common skin condition, psoriasis.
The exact cause of Palmoplantar Pustulosis (PPP) is not known. Possible causes include smoking, bacterial infections (acute or chronic tonsillitis, dental infection, chronic sinusitis), contact allergies (mainly metals), and certain medications. Genetics may play a role in patients with a family history of the disorder. PPP can be diagnosed by examining the affected skin and skin swabs. In some patients, a skin biopsy might also be required.
There is currently no definitive cure for Palmoplantar Pustulosis (PPP), but there are different treatment options available such as Topical steroids, Emollients, Retinoid medications, phototherapy or ultraviolet light therapy, tar ointments, immunosuppressive therapy, and others.
Palmoplantar Pustulosis Market Key Facts
Psoriatic nail involvement is frequently seen in Palmoplantar Pustulosis (PPP), and a family history of psoriasis has also been recorded in 10-42% of patients affected by PPP.
As per a study conducted by Miceli and Schmieder (2020) titled “Palmoplantar Psoriasis”, Palmoplantar Pustulosis (PPP) has an average age of onset between 20 and 60 years of age and shows a clear predilection for females, with a female-to-male ratio of 8:2.
According to a study by Miceli & Schmieder (2021), Palmoplantar psoriasis affects individuals of all ages and comprises 3% to 4% of all cases of psoriasis, which affects 2% to 5% of the population.
To counter unmet market needs and provide better treatment choices for Palmoplantar Pustulosis, pharma and biotech giants are working robustly either on single-agent novel molecules or on the combination and dose modification of standard therapies.
A few major market players in the Palmoplantar Psoriasis market include Aristea Therapeutics (RIST4721), Amgen (OTEZLA), among others.
DelveInsight estimates that the US accounted for the highest number of patients with Palmoplantar Psoriasis (PPP)among the 7MM countries.
According to research studies, it is evident that females are more affected by Palmoplantar Psoriasis as compared to males.
Palmoplantar Pustulosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Palmoplantar Pustulosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Palmoplantar Pustulosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Palmoplantar Pustulosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Palmoplantar Pustulosis Epidemiology Segmentation by –
Total Prevalent Cases of Palmoplantar Psoriasis
Gender-specific Prevalence of Palmoplantar Psoriasis
Morphology-specific Prevalence of Palmoplantar Psoriasis
Palmoplantar Pustulosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Palmoplantar Pustulosis market or expected to get launched during the study period. The analysis covers the Palmoplantar Pustulosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Palmoplantar Pustulosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Palmoplantar Pustulosis Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market
The key companies in the Palmoplantar Pustulosis (PPP) Market include:
Amgen
AbbVie
Kyowa Kirin
AnaptysBio
Merck
Boehringer Ingelheim
And many others.
Palmoplantar Pustulosis (PPP) Therapies covered in the report include:
Brodalumab
Risankizumab
Imsidolimab
Otezla
Spesolimab
RIST4721
And many more
The pipeline of Palmoplantar Pustulosis (PPP) possesses several mid and late-phase therapies under development by key players, expected to hit the market in the near future.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Palmoplantar Pustulosis Competitive Intelligence Analysis
4. Palmoplantar Pustulosis Market Overview at a Glance
5. Palmoplantar Pustulosis Disease Background and Overview
6. Palmoplantar Pustulosis Patient Journey
7. Palmoplantar Pustulosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Palmoplantar Pustulosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Palmoplantar Pustulosis Unmet Needs
10. Key Endpoints of Palmoplantar Pustulosis Treatment
11. Palmoplantar Pustulosis Marketed Products
12. Palmoplantar Pustulosis Emerging Drugs and Latest Therapeutic Advances
13. Palmoplantar Pustulosis Seven Major Market Analysis
14. Attribute Analysis
15. Palmoplantar Pustulosis Market Outlook (In US, EU5, and Japan)
16. Palmoplantar Pustulosis Access and Reimbursement Overview
17. KOL Views on the Palmoplantar Pustulosis Market
18. Palmoplantar Pustulosis Market Drivers
19. Palmoplantar Pustulosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Palmoplantar Pustulosis Pipeline Insight
“Palmoplantar Pustulosis Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across Palmoplantar Pustulosis Market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
